Physician profile
Atef Shaikh
NPI 1578908604
$2,501.29
in general payments reported to CMS, 2019-2025
17 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $860 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.56 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $362.55 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $303.28 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $278.49 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $197.69 | 2024-2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $185.13 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $144.97 | 2024-2025 | Aristada, Lybalvi |
| Abbvie INC. | $125.58 | 2024-2025 | |
| Lundbeck LLC | $123.03 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $97.48 | 2025 | Auvelity |
| Biogen, INC. | $88.43 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $67.73 | 2025 | Jornay Pm |
| Indivior INC. | $40.11 | 2024-2025 | Sublocade |
| Almatica Pharma LLC | $40.11 | 2024-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $28.25 | 2025 | Invega Sustenna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $25.49 | 2025 | Wellbutrin |
| Supernus Pharmaceuticals, INC. | $21.41 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atef Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.